Aksnes Tonje A, Flaa Arnljot, Strand Arne, Kjeldsen Sverre E
Department of Cardiology, Ullevaal University Hospital, N-0407 Oslo, Norway.
Curr Hypertens Rep. 2008 Jun;10(3):175-81. doi: 10.1007/s11906-008-0034-x.
Hypertensive patients have an increased risk of developing atrial fibrillation (AF), which increases cardiovascular morbidity and mortality in this population. Primary prevention is a new strategy in treating AF; previously, it was more common to focus on preventing adverse outcomes and controlling the arrhythmia's rate and rhythm. In this review, we consider the possible preventive effects of antihypertensive treatment on new-onset AF seen in recent trials, especially with blockers of the renin-angiotensin system (RAS). Several secondary analyses of large, randomized trials regarding hypertension and heart failure have shown promising results with benefits beyond the expected blood pressure-lowering effect. A few prospective studies on prevention of AF recurrence with RAS blockade have been published, and more studies are expected to be published in the near future.
高血压患者发生心房颤动（AF）的风险增加，这会增加该人群的心血管发病率和死亡率。一级预防是治疗AF的一项新策略；以前，更常见的是专注于预防不良后果以及控制心律失常的速率和节律。在本综述中，我们考虑了近期试验中抗高血压治疗对新发AF可能的预防作用，尤其是肾素-血管紧张素系统（RAS）阻滞剂的作用。几项关于高血压和心力衰竭的大型随机试验的二次分析已显示出有前景的结果，其益处超出了预期的降压效果。关于使用RAS阻滞剂预防AF复发的一些前瞻性研究已发表，预计在不久的将来会有更多研究发表。
